The trademark application RP2 was filed by Replimune Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on December 19, 2023, and it was registered by office on March 27, 2024 without any oppositions.
The application was filed in English (French was selected as the second language).
The Refusal with reference B 018834663 was partially rejected according to Article 7(1)(b) EUTMR with decision issued on August 20, 2023 by the EUIPO.
Goods And Services
The mark was filed in class 5 with following description of goods:
Viruses for the treatment of cancer
Pharmaceuticals for the treatment of cancer
Biological preparations in the nature of viruses for the treatment of cancer, tumors and oncological diseases and disorders
Biological preparations in the nature of viruses for the treatment of cancer
Pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors and oncological diseases and disorders
Pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors and oncological diseases and disorders
Immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors and oncological diseases and disorders
Gene therapy products, namely, therapeutics for the treatment of cancer, tumors and oncological diseases and disorders.